Open AccessCoronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals
Author(s) -
Airis Y. Collier,
Jingyou Yu,
Katherine McMahan,
Jinyan Liu,
Caroline Atyeo,
Jessica L. Ansel,
Zachary Fricker,
Martha Pavlakis,
Michael Curry,
Catherine Jacob-Dolan,
Het Patel,
Daniel Sellers,
Julia Barrett,
Marjorie Rowe,
Kunza Ahmad,
Annika Gompers,
Ricardo Aguayo,
Abishek Chandrashekar,
Galit Alter,
Michele R. Hacker,
Dan H. Barouch
Publication year - 2021
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiab569
Subject(s) - immunogenicity , immunology , vaccination , virology , coronavirus , antibody , neutralizing antibody , messenger rna , cd8 , medicine , interferon , immune system , biology , covid-19 , disease , infectious disease (medical specialty) , gene , biochemistry
Individuals on immunosuppressive (IS) therapy have increased mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and delayed viral clearance may lead to new viral variants. IS therapy reduces antibody responses following coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccination; however, a comprehensive assessment of vaccine immunogenicity is lacking. Here we show that IS therapy reduced neutralizing, binding, and nonneutralizing antibody functions in addition to CD4 and CD8 T-cell interferon-γ responses following COVID-19 mRNA vaccination compared to immunocompetent individuals. Moreover, IS therapy reduced cross-reactivity against SARS-CoV-2 variants. These data suggest that the standard COVID-19 mRNA vaccine regimens will likely not provide optimal protection in immunocompromised individuals.